|Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.|
|PMID: 19697164 Owner: NLM Status: MEDLINE|
|Venous thromboembolism associated with use of a central venous access system is an urgent problem in patients treated with bevacizumab (bev). We investigated the effectiveness of Doppler ultrasound imaging (DUS) in the early detection of catheter-related thrombosis for avoidance of severe venous thromboembolism. Patients with metastatic colorectal cancer received either FOLFOX-4 + bev or FOLFIRI + bev. DUS was performed on the deep venous system for detection of thrombus formation during the initial cycle of treatment, followed by re-evaluation after the third cycle in patients with asymptomatic thrombus formation. All patients were followed up until treatment was interrupted. Median duration of follow-up was 484 days (range 72-574). Among 41 enrolled patients, curable symptomatic thrombosis occurred in one, and asymptomatic thrombosis in 21 (51.2%). Of 21 patients undergoing re-evaluation, thrombi remained without progression in 17 patients, and enlargement in 4 patients. In two of the patients in whom there was progression, pulmonary embolism occurred after the sixth cycle. In the asymptomatic group, no thrombi developed as far as the superior vena cava in any patient. In the cases of progression, thrombotic enlargement was observed in all the 4 patients, with decreased vascular flow in 2. Using DUS, we were able to detect asymptomatic thrombosis in the early cycles of treatment, indicating its potential in the monitoring of venous thrombi. In the event of an enlarging asymptomatic thrombosis developing into the superior vena cava along with decreased vascular flow, careful follow-up and appropriate anticoagulant therapy may be recommended without increased risk of bleeding.|
|Mitsukuni Suenaga; Nobuyuki Mizunuma; Kokoro Kobayashi; Eiji Shinozaki; Satoshi Matsusaka; Keisho Chin; Yasutoshi Kuboki; Takashi Ichimura; Masato Ozaka; Mariko Ogura; Yoshimasa Fujiwara; Kiyoshi Matsueda; Fumio Konishi; Kiyohiko Hatake|
Related Documents :
|12624634 - Travel and the risk of symptomatic venous thromboembolism.
9299854 - Natural and acquired inhibitors of hemostasis in selected symptomatic outpatients with ...
9405014 - The effect of mobilisation of patients during treatment of thromboembolic disorders wit...
1595704 - Forecasting thrombosis of vascular access with doppler color flow imaging.
7138044 - High-dose vitamin a therapy for darier's disease.
24552634 - New molecule in the etiology of schizophrenia: urotensin ii.
|Type: Clinical Trial; Journal Article Date: 2009-08-21|
|Title: Medical oncology (Northwood, London, England) Volume: 27 ISSN: 1559-131X ISO Abbreviation: Med. Oncol. Publication Date: 2010 Sep|
|Created Date: 2010-08-20 Completed Date: 2010-12-30 Revised Date: 2013-05-27|
Medline Journal Info:
|Nlm Unique ID: 9435512 Medline TA: Med Oncol Country: United States|
|Languages: eng Pagination: 807-14 Citation Subset: IM|
|Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo, 135-8550, Japan. firstname.lastname@example.org|
|APA/MLA Format Download EndNote Download BibTex|
Angiogenesis Inhibitors / administration & dosage, adverse effects*
Antibodies, Monoclonal / administration & dosage, adverse effects*
Antibodies, Monoclonal, Humanized
Anticoagulants / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / administration & dosage, adverse effects, therapeutic use*
Camptothecin / administration & dosage, analogs & derivatives
Catheterization, Central Venous / adverse effects*
Colorectal Neoplasms / complications, drug therapy*
Fluorouracil / administration & dosage
Leucovorin / administration & dosage
Organoplatinum Compounds / administration & dosage
Pulmonary Embolism / etiology, prevention & control
Thrombophilia / drug therapy, etiology*, ultrasonography
Vena Cava, Superior
Venous Thromboembolism / drug therapy, etiology, prevention & control, ultrasonography*
|0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Anticoagulants; 0/Organoplatinum Compounds; 2S9ZZM9Q9V/bevacizumab; 51-21-8/Fluorouracil; 58-05-9/Leucovorin; 7689-03-4/Camptothecin|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The Human Endogenous Retrovirus Link between Genes and Environment in Multiple Sclerosis and in Mult...
Next Document: A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia.